Our dimeric structures pave the way to the structure-based design of ligands capable of modulating the formation of CCR5 and CXCR4 dimers and, in turn, their activity, with therapeutic potential against HIV, cancer, and immune-inflammatory diseases related to these chemokine receptors. Here, CCR5 is linked to cancer.